Anti-Epileptic Effects of FABP3 Ligand MF1 through the Benzodiazepine Recognition Site of the GABA


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
01 Aug 2020
Historique:
received: 14 07 2020
revised: 29 07 2020
accepted: 29 07 2020
entrez: 6 8 2020
pubmed: 6 8 2020
medline: 23 2 2021
Statut: epublish

Résumé

Recently, we developed the fatty acid-binding protein 3 (FABP3) ligand MF1 (4-(2-(1-(2-chlorophenyl)-5-phenyl-1H-pyrazol-3-yl)phenoxy) butanoic acid) as a therapeutic candidate for α-synucleinopathies. MF1 shows affinity towards γ-aminobutyric acid type-A (GABA

Identifiants

pubmed: 32752296
pii: ijms21155525
doi: 10.3390/ijms21155525
pmc: PMC7432285
pii:
doi:

Substances chimiques

Anticonvulsants 0
Fatty Acid Binding Protein 3 0
Ligands 0
Receptors, GABA-A 0
Benzodiazepines 12794-10-4
Flumazenil 40P7XK9392
Diazepam Q3JTX2Q7TU
Pentylenetetrazole WM5Z385K7T

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Front Neurosci. 2016 Jun 09;10:269
pubmed: 27375426
Tohoku J Exp Med. 2008 Mar;214(3):213-20
pubmed: 18323691
J Alzheimers Dis. 2015;49(3):733-41
pubmed: 26484922
Brain. 2020 May 21;:
pubmed: 32437558
Int J Mol Sci. 2019 Oct 28;20(21):
pubmed: 31661838
Neuropharmacology. 2017 May 1;117:1-13
pubmed: 28093211
Biochim Biophys Acta. 1998 Apr 22;1391(3):287-306
pubmed: 9555061
Mol Psychiatry. 2020 May 6;:
pubmed: 32376999
J Neurosci. 2018 Dec 5;38(49):10411-10423
pubmed: 30341178
Drug Des Devel Ther. 2014 Nov 07;8:2263-71
pubmed: 25422586
Neurosci Lett. 2012 Aug 15;523(2):115-8
pubmed: 22750154
Pharmaceuticals (Basel). 2020 Mar 10;13(3):
pubmed: 32164340
Pharmacotherapy. 2013 Mar;33(3):330-43
pubmed: 23400943
J Pharmacol Sci. 2013;121(1):84-7
pubmed: 23257655
Neurochem Res. 2017 Jul;42(7):1873-1888
pubmed: 28290134
Bioorg Med Chem Lett. 2013 Mar 15;23(6):1662-6
pubmed: 23395658
Int J Mol Sci. 2020 Mar 23;21(6):
pubmed: 32210174
Eur J Pharmacol. 1984 Mar 2;98(3-4):337-45
pubmed: 6327331
Acta Neurol Scand. 2008 Aug;118(2):69-86
pubmed: 18384456
J Chem Neuroanat. 1996 Dec;12(2):113-22
pubmed: 9115666
Cold Spring Harb Perspect Med. 2016 May 02;6(5):
pubmed: 26801895
Brain Res. 2019 Mar 15;1707:190-197
pubmed: 30496735
J Alzheimers Dis. 2017;60(1):211-223
pubmed: 28826176
J Biol Chem. 2014 Jul 4;289(27):18957-65
pubmed: 24855640
Neuropharmacology. 2019 May 15;150:164-174
pubmed: 30930168
Curr Top Med Chem. 2005;5(1):3-14
pubmed: 15638774
Sci Rep. 2017 Apr 24;7:46654
pubmed: 28436443
Alzheimers Dement. 2020 Jun 16;:
pubmed: 32543726
Epilepsy Res. 1993 Feb;14(2):139-48
pubmed: 8095893
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):105-13
pubmed: 14687864
N Engl J Med. 1998 Apr 2;338(14):970-6
pubmed: 9521986
Eur J Pharmacol. 2014 Feb 5;724:152-60
pubmed: 24374009
Alzheimers Res Ther. 2017 Jul 28;9(1):52
pubmed: 28750675
Ann N Y Acad Sci. 1999 Apr 30;868:645-53
pubmed: 10414349
Br Med J. 1967 Jul 8;3(5557):85-8
pubmed: 4961468
Annu Rev Pharmacol Toxicol. 2014;54:483-507
pubmed: 24160694
Mol Neurobiol. 2018 Apr;55(4):3577-3591
pubmed: 28516430
Brain Res Bull. 2020 Jul;160:107-120
pubmed: 32380189
Br J Pharmacol. 1997 Jul;121(6):1171-9
pubmed: 9249254
Eur J Neurosci. 2000 Jul;12(7):2205-10
pubmed: 10947798
Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
pubmed: 4110397
Neuron. 2007 Dec 6;56(5):763-70
pubmed: 18054854
Epilepsy Res. 2002 Apr;49(2):109-20
pubmed: 12049799
Neurosci Res. 2001 Dec;41(4):397-9
pubmed: 11755227
Epilepsia. 1999;40 Suppl 1:S9-20; discussion S21-2
pubmed: 10421557
Neuron. 2003 May 8;38(3):433-45
pubmed: 12741990
Trends Pharmacol Sci. 2000 Jan;21(1):16-9
pubmed: 10637650

Auteurs

Yasushi Yabuki (Y)

Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Department of Genomic Neurology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto 860-0811, Japan.

Jiaqi Liu (J)

Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.

Ichiro Kawahata (I)

Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.

Hisanao Izumi (H)

Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.

Yasuharu Shinoda (Y)

Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.

Kohei Koga (K)

Department of Neurophysiology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
Department of Neurophysiology, Graduate School of Medicine, Hirosaki University, Hirosaki 036-8216, Japan.

Shinya Ueno (S)

Department of Neurophysiology, Graduate School of Medicine, Hirosaki University, Hirosaki 036-8216, Japan.

Norifumi Shioda (N)

Department of Genomic Neurology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto 860-0811, Japan.

Kohji Fukunaga (K)

Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH